Charles River and Lundbeck Enter Agreement Utilizing AI-Powered Logica® to Advance the Discovery of Novel Drugs for Neurological Disease

CRL 10.02.2024

Full Press ReleaseSEC FilingsOur CRL Tweets

About Gravity Analytica

Recent News

  • 01.21.2025 - Charles River Expands Apollo™ Ecosystem, Offering Bespoke Client Experiences
  • 01.16.2025 - Charles River and Akron Bio Announce Collaboration to Enhance Operations with Integration of CGMP Materials into Cell Therapy Platform
  • 01.14.2025 - Charles River Laboratories at the 43rd Annual J.P. Morgan Healthcare Conference

Recent Filings

  • 01.14.2025 - 8-K Current report
  • 11.12.2024 - 4 Statement of changes in beneficial ownership of securities
  • 11.08.2024 - SC 13G Statement of Beneficial Ownership by Certain Investors

Logica®, an offering fromCharles River and Valo Health, will be leveraged to progress Lundbeck’s research into disorders of the central nervous system

WILMINGTON, Mass.--(BUSINESS WIRE)--Oct. 2, 2024--Charles River Laboratories International, Inc.(NYSE: CRL) today announced an agreement with H. Lundbeck A/S (Lundbeck) to utilizeLogica®to progress critical brain disease research.

“We are excited to partner with Lundbeck as they work toward the discovery of novel treatments for neurodegenerative disease,” said ProfessorJulie Frearson, Ph.D., Senior Vice President and Chief Scientific Officer, Charles River. “Logica’s integrated, AI-augmented process allows us to be an agile partner, and combined with Lundbeck’s industry-leading neurology expertise, we look forward to a successful collaboration.”

Logica is an Artificial Intelligence (AI) powered end-to-end drug discovery solution that translates biological insights into optimized preclinical candidates by leveraging the integration ofValo Health’sAI-powered Opal Computational PlatformTM and Charles River’s leading expertise in drug discovery and preclinical development. Through the agreement, Lundbeck will deploy Logica with the aim of creating optimized small molecules that lead to novel therapies for neurological research.

“To make a significant impact on neurological diseases today, you need to be able to work on unprecedented molecular targets with causal biology,” saidTarek Samad, Senior Vice President and Head ofGlobal Researchat Lundbeck. “Partnering with Logica will allow us to use a unique tool set, including AI-driven approaches, to overcome drug design challenges which often slow down the translation of promising targets into drug candidates.”

About LogicaIn 2022,Charles River and Valo Healthlaunched Logica, providing clients with transformed drug discovery with a single integrated offering seamlessly translating targets to candidate nomination under a partnering business model. Logica utilizes industry-leading predictive models, chemical design, and synthesis capabilities, DNA-encoded libraries,in silicohigh throughput screening from Valo’s Opal Computational Platform as well as Charles River’s leading capabilities in all aspects of discovery optimization including high throughput screening, medicinal chemistry, ADME, biology, pharmacology, and ultimately safety testing and IND submission, joining together for the first time to create a computation-powered, unified target-to-candidate offering.

AboutValo HealthValo Health, Incis a biotechnology company focused on utilizing large scale data and AI-driven computation to discover and develop therapeutics. Valo aims to fully integrate humancentric data across the entire drug development life cycle into a single unified architecture, thereby accelerating the discovery and development of life-changing drugs while simultaneously reducing costs, time, and failure rates. The company’s Opal Computational PlatformTM is an end-to-end drug discovery and development platform designed to transform data into valuable insights that may accelerate discoveries and enable Valo to advance a robust pipeline of programs. Learn more about Valo by visitingvalo​health​.com.

About Charles RiverCharles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visitwww.criver.com.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241002073611/en/

Charles River Investor:Todd Spencer,Corporate Vice President, Investor Relations781.222.6455todd.spencer@crl.com

Charles River Media:Amy CianciarusoCorporate Vice President & Chief Communications Officer+1-781-222-6168amy.cianciaruso@crl.com

Valo Health Media:Olivia Offnerpress@flagshippioneering.​com

Source:Charles River Laboratories International, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com